Strontium-89 chloride in the treatment of bone metastases from breast cancer.

Abstract

Sixty-four patients with painful metastatic breast cancer in bone were treated with 2 MBq/kg of strontium-89 chloride as a single intravenous injection. Patients were followed with records of medication, hematology parameters, serial bone and Sr-89 bremsstrahlung images and with a point pain score scale (10-0). The response was assessed during a 6-month period of follow-up. Fifty-two of 64 patients (81%) showed at least a moderate improvement. Eighteen out of the 52 responders showed a dramatic decrease in bone pain (35%), 21 (40%) presented a satisfactory response and in 13 cases (25%) the response was moderate. Only 12 patients (19%) from the whole group did not feel any improvement on pain palliation. A statistically significant decrease of pretreatment levels of platelets and leukocyte counts was observed after 4-6 weeks of therapy in 50 (70%) patients. Although most patients showed no change in their bone scans after 3 months of treatment, an obvious improvement was observed in 3 of them. Furthermore no additional painful metastases on their bone scintigraphic images were observed. The selective strontium-89 local uptake in metastatic sites was also confirmed directly by bremsstrahlung scans which were absolutely comparable to the respective 99mTc bone scans. Precautions have been taken against Sr-89 contamination from the patients' blood or excretions.

Statistics

050100'02'04'06'08'10'12'14'16
Citations per Year

119 Citations

Semantic Scholar estimates that this publication has 119 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Baziotis1998Strontium89CI, title={Strontium-89 chloride in the treatment of bone metastases from breast cancer.}, author={Nikos Baziotis and E N Yakoumakis and Athanassios Zissimopoulos and X{\'e}nia Geronicola-Trapali and Julia Malamitsi and Charalambos Proukakis}, journal={Oncology}, year={1998}, volume={55 5}, pages={377-81} }